Akron-based FMI Technologies is working on a new tool that can peel images of the brain back like an onion to the molecular level � where the cell-killing processes of neurological degenerative diseases percolate. That's good news for physicians and others who, today, must wait for real physical damage to occur before they can treat diseases like Alzheimer's and Parkinson's. The company currently is perfecting an ultra-high resolution imaging technology that not only detects physical changes in brain tissue but chemical processes that can lead to damage. Buoyed by the success of clinical trials using similar technology for the early detection of breast cancer, FMI is now pursuing a prototype of its ScintiStar™ Neuro system. Clinical trials for ScintiStar^TM await.